The 2014 recommendations on managing multiple sclerosis in reproductive-aged women predate most of the current disease-modifying therapies and nearly all of the lactation safety data. Neurology and obstetric experts screened 774 papers from PubMed, LactMed and ClinicalTrials.gov and produced updated consensus guidance covering pregnancy, lactation and the years around them.
The substantive change is a shift from stopping therapy to timing it. Disease activity can usually be controlled through the childbearing period by continuing or strategically timing many disease-modifying therapies, balancing maternal disease control against fetal exposure, rather than by a blanket washout before conception. Multiple sclerosis itself is not generally associated with adverse pregnancy outcomes, though some studies report slightly raised risks of lower birthweight, preterm birth and operative delivery. The postpartum period is flagged as one of raised medical and psychological risk requiring close follow-up. After childbearing, the emphasis moves to therapy-associated infection risk, cervical dysplasia screening and the menopausal transition.
This is expert consensus assembled from observational and registry data, not trial evidence, and drug-specific decisions belong with the neurologist. What it changes for obstetric practice is the default posture: a woman with multiple sclerosis planning pregnancy should be referred for a joint discussion about which therapy and when, rather than advised to stop treatment and conceive. Abrupt withdrawal of some agents carries a rebound risk that is worse than the exposure being avoided.
- Refer for joint neurology and obstetric planning before conception rather than advising a blanket stop
- Do not stop disease-modifying therapy abruptly — rebound disease activity is a real risk with some agents
- Plan postpartum follow-up explicitly: relapse and psychological risk both rise
- Keep cervical screening on schedule; some therapies raise dysplasia and infection risk
- Reassure that multiple sclerosis itself is not generally associated with adverse pregnancy outcomes
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free